Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Accounts Payable & Accrued Expense

: $2,965 Mil (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

Regeneron Pharmaceuticals's quarterly accounts payable & accrued expense increased from Jun. 2023 ($2,723 Mil) to Sep. 2023 ($3,181 Mil) but then declined from Sep. 2023 ($3,181 Mil) to Dec. 2023 ($2,965 Mil).

Regeneron Pharmaceuticals's annual accounts payable & accrued expense declined from Dec. 2021 ($2,771 Mil) to Dec. 2022 ($2,663 Mil) but then increased from Dec. 2022 ($2,663 Mil) to Dec. 2023 ($2,965 Mil).

Regeneron Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for Regeneron Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

1,629.50

2,119.70

2,770.80

2,663.40

2,964.50

Regeneron Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense																2,663.40	2,673.80	2,723.30	3,181.30	2,964.50

Regeneron Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (NAS:REGN) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

REGN:Mexico RGO:Germany RGO:Germany REGN34:Brazil

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Executives

Bonnie L Bassler	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Arthur F Ryan	director	CITIZENS FINANCIAL GROUP, INC, 600 WASHINGTON BOULEVARD, STAMFORD CT 06901
George Yancopoulos	director, officer: President and CSO	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Huda Y Zoghbi	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Marion Mccourt	officer: SVP Commercial	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Michael S Brown	director
Christopher R. Fenimore	officer: VP, Controller	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Andrew J Murphy	officer: EVP Research	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Kathryn Guarini	director	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
David P Schenkein	director	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Van Plew Daniel P	officer: EVP & General Mgr Industrial O	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Robert E Landry	officer: SVP Fin, Dep CFO	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Christine A Poon	director	C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Neil Stahl	officer: SVP, Preclinical Development	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Joseph L Goldstein	director	DEPT OF PHARMACOLOGY K5 YUVER OF TEXAS, 5323 HARRY HINES BLVD, DALLAS TX 75390